Pharmaceutical Executive, Sep 1, 2011 - Pharmaceutical Executive

ADVERTISEMENT

Pharmaceutical Executive, Sep 1, 2011
Features
Front and Center in the Fight against TB
By William Looney
Pharm Exec talks to Dr. Mel Spigelman, President and CEO of the TB Alliance, about the organization's tuberculosis priorities.
Should the US Gamble with Risk Sharing?
By Julian Upton
Especially when payers come to the table holding the best cards — leaving industry second-guessing its strategy.
Pharm Exec's 10th Annual Industry Audit
By Bill Trombetta
Bill Trombetta surveys the landscape of pharma financials over the past year, and shows which companies rode the wave to the top of the industry in delivering value to shareholders.
The Power of Product Development Partnership
By William Looney
Can cooperative ties between Big Pharma, NGOs, government, and international organizations pay the freight in making the fight against neglected diseases a permanent fix in global health?
Pharma and Social Media: Ready to Make Nice?
By Peter Houston
The time is right for industry to overcome its social media phobia once and for all.
Special Section
Build It and They Will Come
By Marylyn Donahue
Orlando's new Burnham Research Institute bolsters the region's hold on medical meetings
(Some) Booths Beckon
By John Ruane
What some pharma companies are doing about the increasing restrictions of face-to-face interaction between industry and prescribing physicians
From the Editor
Get Back in the Box!
By William Looney
Despite the gloom, most forecasts show the US will stay atop the industry in profits for at least the next generation of products.
Columns
The Power of Observation
By Richard Gilkich
Observational studies present a compelling real-world corollary to the classic randomized clinical trial.
Innovating Around Innovation
Richard Barker, former Director General of ABPI, proposes a new agenda on how to restore public confidence in the value behind science.
A Long, Slow Walk Toward the Altar
By Al Topin
Agency/client relationships still take time to build into successful marriages in this age of digital connections and me-first attitudes
Bridging the Hidden Hurdle in Cancer Cures
By Don Creighton
Diagnostics can bost the efficacy of drug treatments, but delivering the promise depends on a predictible pathway to reimbursement.
Complex Biologics: The View from Teva
By Dr. Jill Conner
Industry and regulators alike must graple with the sensitivities associated with developing biosimilar drugs.
Rebates and Reform
By Jill Wechsler
User-fee renewal legislation sets the stage for new policies affecting reimbursement, research, and regulatory oversight.
Turning the Ins and Outs of Marketing Inside-Out
By Bill Drummy
Keeping your finger on the pulse of consumers leads to better, more actionable insights—and better results.

ADVERTISEMENT

Click here